Aug 13, 2020
Leap Therapeutics Reports Second Quarter 2020 Financial Results
Jun 22, 2020
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Jun 18, 2020
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
Jun 17, 2020
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jun 11, 2020
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
May 14, 2020
Leap Therapeutics Reports First Quarter 2020 Financial Results
Apr 23, 2020
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
Apr 02, 2020
Imaging Endpoints' Novel Radiomics Technology Helps Identify DKK1 Biomarker
Mar 16, 2020
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Jan 23, 2020
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
Nov 14, 2019
Leap Therapeutics Reports Third Quarter 2019 Financial Results
Sep 04, 2019
Leap Therapeutics to Present at Upcoming Investor Conferences
Aug 09, 2019
Leap Therapeutics Reports Second Quarter 2019 Financial Results
Aug 06, 2019
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Jul 25, 2019
Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update
Jun 11, 2019
Leap Therapeutics to Present at the 2019 Raymond James Life Sciences and MedTech Conference
Apr 01, 2019
Leap Therapeutics Reports Clinical Update and 2018 Financial Results
Mar 18, 2019
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
Mar 08, 2019
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
Jan 31, 2019
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants